Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar frankyz669 (< 20) Submitted: 9/3/2010 10:23:24 AM : Outperform Start Price: $2.92 SNTA Score: +25.22

Magic Formula - though speculative. I think it made the MF list because of huge cash infusion from selling its position with another partner.

Featured Broker Partners


Advertisement